Compare CHCT & VOGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHCT | VOGX |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 514.6M | 456.5M |
| IPO Year | 2015 | 2026 |
| Metric | CHCT | VOGX |
|---|---|---|
| Price | $14.93 | $32.02 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $18.00 | N/A |
| AVG Volume (30 Days) | ★ 359.4K | 316.6K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | ★ 11.07% | N/A |
| EPS Growth | ★ 134.78 | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $121,195,000.00 | N/A |
| Revenue This Year | $9.06 | N/A |
| Revenue Next Year | $8.61 | N/A |
| P/E Ratio | $125.17 | ★ N/A |
| Revenue Growth | ★ 4.67 | N/A |
| 52 Week Low | $13.23 | $14.80 |
| 52 Week High | $19.17 | $35.50 |
| Indicator | CHCT | VOGX |
|---|---|---|
| Relative Strength Index (RSI) | 35.36 | 100.00 |
| Support Level | $15.07 | N/A |
| Resistance Level | $16.09 | N/A |
| Average True Range (ATR) | 0.38 | 4.39 |
| MACD | 0.01 | 1.79 |
| Stochastic Oscillator | 50.67 | 86.39 |
Community Healthcare Trust Inc is an integrated healthcare real estate company in the United States. The company owns and acquires, or finances, real estate properties that are leased to hospitals, doctors, healthcare systems, or other healthcare service providers in non-urban markets. The company derives the majority of its revenues from its real estate property and mortgage notes portfolio. The company's rental and mortgage interest income is recognized based on contractual arrangements with its tenants and borrowers.
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.